The FKBP5-Gene in Depression and Treatment Response-an Association Study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort

Magnus Lekman, Gonzalo Laje, Dennis Charney, A. John Rush, Alexander F. Wilson, Alexa J M Sorant, Robert Lipsky, Stephen R. Wisniewski, Husseini Manji, Francis J. McMahon, Silvia Paddock

Research output: Contribution to journalArticle

Abstract

Background: In a recent study of several antidepressant drugs in hospitalized, non-Hispanic White patients, Binder et al. reported association of markers located within the FKBP5 gene with treatment response after 2 and 5 weeks. Individuals homozygous for the TT-genotype at one of the markers (rs1360780) reported more depressive episodes and responded better to antidepressant treatment. There was no association between markers in FKBP5 and disease. The present study aimed at studying the associated FKBP5 markers in the ethnically diverse Sequenced Treatment Alternatives to Relieve Depression (STAR*D) sample of non-hospitalized patients treated with citalopram. Methods: We used clinical data and DNA samples from 1809 outpatients with non-psychotic major depressive disorder (DSM-IV criteria), who received up to 14 weeks of citalopram. A subset of 1523 patients of White non-Hispanic or Black race was matched with 739 control subjects for a case-control analysis. The markers rs1360780 and rs4713916 were genotyped on the Illumina platform. TaqMan-assay was used for marker rs3800373. Results: In the case-control analysis, marker rs1360780 was significantly associated with disease status in the White non-Hispanic sample after correction for multiple testing. A significant association was also found between rs4713916 and remission. Markers rs1360780 and rs4713916 were in strong linkage disequilibrium in the White non-Hispanic but not in the Black population. There was no significant difference in the number of previous episodes of depression between genotypes at any of the three markers. Conclusions: These results indicate that FKBP5 is an important target for further studies of depression and treatment response.

Original languageEnglish (US)
Pages (from-to)1103-1110
Number of pages8
JournalBiological Psychiatry
Volume63
Issue number12
DOIs
StatePublished - Jun 15 2008
Externally publishedYes

Fingerprint

Depression
Citalopram
Antidepressive Agents
Genes
Genotype
Linkage Disequilibrium
Major Depressive Disorder
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders
Outpatients
DNA
Population

Keywords

  • Chaperone
  • depression
  • genome
  • HPA-axis
  • stress

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

The FKBP5-Gene in Depression and Treatment Response-an Association Study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. / Lekman, Magnus; Laje, Gonzalo; Charney, Dennis; Rush, A. John; Wilson, Alexander F.; Sorant, Alexa J M; Lipsky, Robert; Wisniewski, Stephen R.; Manji, Husseini; McMahon, Francis J.; Paddock, Silvia.

In: Biological Psychiatry, Vol. 63, No. 12, 15.06.2008, p. 1103-1110.

Research output: Contribution to journalArticle

Lekman, M, Laje, G, Charney, D, Rush, AJ, Wilson, AF, Sorant, AJM, Lipsky, R, Wisniewski, SR, Manji, H, McMahon, FJ & Paddock, S 2008, 'The FKBP5-Gene in Depression and Treatment Response-an Association Study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort', Biological Psychiatry, vol. 63, no. 12, pp. 1103-1110. https://doi.org/10.1016/j.biopsych.2007.10.026
Lekman, Magnus ; Laje, Gonzalo ; Charney, Dennis ; Rush, A. John ; Wilson, Alexander F. ; Sorant, Alexa J M ; Lipsky, Robert ; Wisniewski, Stephen R. ; Manji, Husseini ; McMahon, Francis J. ; Paddock, Silvia. / The FKBP5-Gene in Depression and Treatment Response-an Association Study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. In: Biological Psychiatry. 2008 ; Vol. 63, No. 12. pp. 1103-1110.
@article{1d7d863f39934484a86fc52afd2acd7e,
title = "The FKBP5-Gene in Depression and Treatment Response-an Association Study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort",
abstract = "Background: In a recent study of several antidepressant drugs in hospitalized, non-Hispanic White patients, Binder et al. reported association of markers located within the FKBP5 gene with treatment response after 2 and 5 weeks. Individuals homozygous for the TT-genotype at one of the markers (rs1360780) reported more depressive episodes and responded better to antidepressant treatment. There was no association between markers in FKBP5 and disease. The present study aimed at studying the associated FKBP5 markers in the ethnically diverse Sequenced Treatment Alternatives to Relieve Depression (STAR*D) sample of non-hospitalized patients treated with citalopram. Methods: We used clinical data and DNA samples from 1809 outpatients with non-psychotic major depressive disorder (DSM-IV criteria), who received up to 14 weeks of citalopram. A subset of 1523 patients of White non-Hispanic or Black race was matched with 739 control subjects for a case-control analysis. The markers rs1360780 and rs4713916 were genotyped on the Illumina platform. TaqMan-assay was used for marker rs3800373. Results: In the case-control analysis, marker rs1360780 was significantly associated with disease status in the White non-Hispanic sample after correction for multiple testing. A significant association was also found between rs4713916 and remission. Markers rs1360780 and rs4713916 were in strong linkage disequilibrium in the White non-Hispanic but not in the Black population. There was no significant difference in the number of previous episodes of depression between genotypes at any of the three markers. Conclusions: These results indicate that FKBP5 is an important target for further studies of depression and treatment response.",
keywords = "Chaperone, depression, genome, HPA-axis, stress",
author = "Magnus Lekman and Gonzalo Laje and Dennis Charney and Rush, {A. John} and Wilson, {Alexander F.} and Sorant, {Alexa J M} and Robert Lipsky and Wisniewski, {Stephen R.} and Husseini Manji and McMahon, {Francis J.} and Silvia Paddock",
year = "2008",
month = "6",
day = "15",
doi = "10.1016/j.biopsych.2007.10.026",
language = "English (US)",
volume = "63",
pages = "1103--1110",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "12",

}

TY - JOUR

T1 - The FKBP5-Gene in Depression and Treatment Response-an Association Study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort

AU - Lekman, Magnus

AU - Laje, Gonzalo

AU - Charney, Dennis

AU - Rush, A. John

AU - Wilson, Alexander F.

AU - Sorant, Alexa J M

AU - Lipsky, Robert

AU - Wisniewski, Stephen R.

AU - Manji, Husseini

AU - McMahon, Francis J.

AU - Paddock, Silvia

PY - 2008/6/15

Y1 - 2008/6/15

N2 - Background: In a recent study of several antidepressant drugs in hospitalized, non-Hispanic White patients, Binder et al. reported association of markers located within the FKBP5 gene with treatment response after 2 and 5 weeks. Individuals homozygous for the TT-genotype at one of the markers (rs1360780) reported more depressive episodes and responded better to antidepressant treatment. There was no association between markers in FKBP5 and disease. The present study aimed at studying the associated FKBP5 markers in the ethnically diverse Sequenced Treatment Alternatives to Relieve Depression (STAR*D) sample of non-hospitalized patients treated with citalopram. Methods: We used clinical data and DNA samples from 1809 outpatients with non-psychotic major depressive disorder (DSM-IV criteria), who received up to 14 weeks of citalopram. A subset of 1523 patients of White non-Hispanic or Black race was matched with 739 control subjects for a case-control analysis. The markers rs1360780 and rs4713916 were genotyped on the Illumina platform. TaqMan-assay was used for marker rs3800373. Results: In the case-control analysis, marker rs1360780 was significantly associated with disease status in the White non-Hispanic sample after correction for multiple testing. A significant association was also found between rs4713916 and remission. Markers rs1360780 and rs4713916 were in strong linkage disequilibrium in the White non-Hispanic but not in the Black population. There was no significant difference in the number of previous episodes of depression between genotypes at any of the three markers. Conclusions: These results indicate that FKBP5 is an important target for further studies of depression and treatment response.

AB - Background: In a recent study of several antidepressant drugs in hospitalized, non-Hispanic White patients, Binder et al. reported association of markers located within the FKBP5 gene with treatment response after 2 and 5 weeks. Individuals homozygous for the TT-genotype at one of the markers (rs1360780) reported more depressive episodes and responded better to antidepressant treatment. There was no association between markers in FKBP5 and disease. The present study aimed at studying the associated FKBP5 markers in the ethnically diverse Sequenced Treatment Alternatives to Relieve Depression (STAR*D) sample of non-hospitalized patients treated with citalopram. Methods: We used clinical data and DNA samples from 1809 outpatients with non-psychotic major depressive disorder (DSM-IV criteria), who received up to 14 weeks of citalopram. A subset of 1523 patients of White non-Hispanic or Black race was matched with 739 control subjects for a case-control analysis. The markers rs1360780 and rs4713916 were genotyped on the Illumina platform. TaqMan-assay was used for marker rs3800373. Results: In the case-control analysis, marker rs1360780 was significantly associated with disease status in the White non-Hispanic sample after correction for multiple testing. A significant association was also found between rs4713916 and remission. Markers rs1360780 and rs4713916 were in strong linkage disequilibrium in the White non-Hispanic but not in the Black population. There was no significant difference in the number of previous episodes of depression between genotypes at any of the three markers. Conclusions: These results indicate that FKBP5 is an important target for further studies of depression and treatment response.

KW - Chaperone

KW - depression

KW - genome

KW - HPA-axis

KW - stress

UR - http://www.scopus.com/inward/record.url?scp=44349188699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44349188699&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2007.10.026

DO - 10.1016/j.biopsych.2007.10.026

M3 - Article

C2 - 18191112

AN - SCOPUS:44349188699

VL - 63

SP - 1103

EP - 1110

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 12

ER -